% | $
Quotes you view appear here for quick access.

ZIOPHARM Oncology, Inc. Message Board

  • rob_cos rob_cos Jan 29, 2013 3:49 PM Flag

    parmaiweb "improved convenience will drive high PAli uptake, especially once it becomes available in EU"

    I posted the full article on the investorvillage ZIOP board. Volume is pouring in = 400k and 500k blocks. Final cleanup.

    IOP - pharmiweb " improved convenience over IFOS—namely, reduced hospital stay & alleviation of need for hydration—will offset higher price of palifosfamide & will drive high uptake, especially once it becomes available in EU"

    Final Paragraph:

    "Although we believe that palifosfamide will gain approval for the treatment of soft tissue sarcoma, it will likely not have a significant impact on overall survival outcomes for patients, being largely equivalent to ifosfamide in this regard, although palifosfamide will demonstrate superior progression-free survival over doxorubicin alone," said Decision Resources Therapy Leader of Oncology Joanne Graham, Ph.D. "The key advantages of palifosfamide will be reduced neurotoxicity and improved ease of administration, especially once the oral capsule is available. It's anticipated that the improved convenience over ifosfamide—namely, reduced hospital stay and alleviation of the need for hydration—will offset the inevitable higher price of palifosfamide and will drive high uptake, especially once it becomes available in Europe."

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
9.03+0.46(+5.37%)3:32 PMEDT